Zymeworks buys cash-generating COPD asset for $929m

Theravance deal gives biotech firm a marketed medicine, reliable cash flow and more room to invest in future therapies. What if the next breakthrough cancer medicine isn’t funded by another round of venture capital, but by a drug that’s already sitting on pharmacy shelves? That’s the bigger story behind Zymeworks’ $929 million acquisition of Theravance […] The post Zymeworks buys cash-generating COPD asset for $929m appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.